Cellogen Therapeutics awaits CDSCO nod for human trial on its ‘bi-specific 3rd generation’ CAR-T therapy
Biotech start-up Cellogen Therapeutics is awaiting a nod from the Central Drugs Standard Control Organisation (CDSCO) to start its first-in-human (Phase I) trials on its
